(A) In vivo expression of Tat has no
effect on total GSK3β level in any of the four brain regions we examined.
(B) In vivo Tat expression leads to
upregulated activity of GSK3β (decreased ratio of
p-GSK3β-S9/t-GSK3β) in cortex, striatum and hippocampus, but not
cerebellum (p = 0.077). (C-D) Western blots show
that Tat expression in vivo leads to an increased total
CaMKIIβ level in cortex, striatum, and hippocampus (C,
cerebellum: p = 0.09), and upregulated CaMKIIβ activity
(increased p-CaMKIIβ-T287/t-CaMKIIβ ratio) in all four regions
examined (* p < 0.05 vs. corresponding control). In A-D,
Ctx: cortex; Cb: cerebellum; Str: striatum; Hipp: hippocampus. Data in
A-D are based on the results from N=3 individual Tat+ and Tat− mice,
each from a different litter.